Cancer chemotherapy in the elderly

Area of Science:

• Geriatric Oncology
• Gastrointestinal Oncology
• Clinical Pharmacology

Background:

• Gastrointestinal malignancies are prevalent in the elderly population in the U.S.
• Controversy exists regarding chemotherapy's role in elderly patients due to perceived increased toxicity and reduced benefit.
• Limited definitive data exists on chemotherapy's specific impact on this demographic.

Purpose of the Study:

• To review the literature on chemotherapy pharmacology, efficacy, and toxicity in elderly patients with gastrointestinal malignancies.
• To address the controversy surrounding chemotherapy use in older adults.
• To provide general observations based on current understanding.

Main Methods:

• Literature review of chemotherapy agents used for gastrointestinal malignancies.
• Analysis of data concerning efficacy, toxicity, and pharmacology in the elderly.
• Synthesis of observations regarding age, functional parameters, and treatment outcomes.

Main Results:

• Most chemotherapy agents do not exhibit increased toxicity in the elderly.
• Dosing and treatment regimens should prioritize functional parameters over chronological age.
• Chemotherapy for advanced gastrointestinal malignancies generally offers marginal efficacy and carries potential toxicity for all age groups.

Conclusions:

• Chemotherapy's role in elderly patients with gastrointestinal cancers requires careful consideration of individual functional status.
• Further prospective studies are essential to evaluate efficacy, toxicity, and quality of life impacts.
• Current evidence suggests a need for personalized treatment approaches in geriatric oncology.